The role of first-generation EGFR TKI icotinib in the adjuvant setting was studied in the Chinese EVIDENCE phase III trial enrolling 322 patients with resected stage II–IIIA EGFR mutant + NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.